Randomized Phase II Clinical Trial Of Pracinostat Set For Front Line Myelodysplastic Syndrome
Monday, September 8, 2014 - 09:31
in Health & Medicine
Enrollment in a randomized Phase II clinical trial of Pracinostat in combination with azacitidine in patients with previously untreated intermediate-2 or high-risk myelodysplastic syndrome (MDS) has been completed. The multi-center, placebo-controlled, double-blind study enrolled a total of 108 patients with a one-to-one randomization. The Company plans to unblind the study approximately six months after the last patient was enrolled and report topline data in Q1 2015. read more